Strengthening Medicare Advantage: Regulatory Changes Impacting Hospitals

As the Centers for Medicare & Medicaid Services (CMS) unveil proposed regulatory changes under CMS-4208-F, hospitals are navigating unforeseen outcomes from strengthened patient protections in the Medicare Advantage (MA) 2026 Final Rule. The rule aims to enhance transparency and standardize notice delivery, shifting focus back onto hospitals by increasing pressures in utilization management and tightening both financial and operational oversight.

Aetna's policy revision significantly alters the traditional framework for inpatient denial handling. More broadly, MA plans have enacted operational changes such as updating peer-to-peer (P2P) denial pathways, expediting clinical documentation submissions, and modifying Diagnosis-Related Group (DRG) contract payment structures. These shifts may respond to hospital practices under CMS-4201-F or the stipulations of CMS-4208-F regarding direct beneficiary notifications through the Integrated Denial Notice (IDN).

The IDN is intended to unify denial communications into a standardized format, detailing coverage, payment decisions, and appeal rights. CMS mandates its issuance upon an adverse organizational determination, including ongoing reviews, to minimize confusion and ensure beneficiaries receive coherent information regarding denied or reduced services.

Hospitals face significant operational impacts if an MA plan denies an inpatient care level while a patient is hospitalized. Prompt notice and appeal opportunities must be ensured, highlighting the logistical challenge of delivering the IDN in real-time. Personal delivery is impractical for MA plans, and mailed notifications may reach patients post-discharge, misaligning with regulatory intentions.

Hospitals could play an active role since they are directly accessible to patients during determination, taking on the task of notifying patients about MA plan denials and reinforcing their appeal rights. This involvement might be pragmatic and essential as regulatory compliance demands evolve.

The question arises whether hospitals should offer the Appointment of Representative (AOR) form (CMS-1696) during denial notifications. Presenting the AOR could empower patients to appoint representatives for the appeals process. Although not mandated by CMS, integrating the AOR may promote transparency and support access to the appeals process.

Integrating the AOR alongside the IDN might benefit patients and families by enabling informed action and ensuring continuity in pursuing appeals. This aligns with CMS's aim to enhance beneficiary rights awareness. However, incorporating these components requires training, standardized workflows, and defined roles within case management frameworks. As MA plans exert more rigorous controls, patient and family engagement in the appeals process becomes increasingly necessary to effectively navigate payer dynamics.